ReviewCurrent opinion in HIV and AIDS2016
Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population.
Review in Current opinion in HIV and AIDS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 244 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
244 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Burden of metabolic syndrome in the global adult HIV-infected population: a systematic review and meta-analysis.BMC public health · 2024Pooled it
- Lifetime prevalence and adherence rate of cervical cancer screening among women living with HIV: a systematic review and meta-analysis.Journal of the International AIDS Society · 2023Pooled it
- Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial.AIDS (London, England) · 2026Trial
- Trial
- Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a "shock and kill" strategy for ART-free virological control: a phase II single-arm study.Signal transduction and targeted therapy · 2024Trial
- Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV.Antimicrobial agents and chemotherapy · 2021Trial
- Trial
- "Cure" Versus "Clinical Remission": The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication.AIDS and behavior · 2020Trial
- The effect of varenicline on mood and cognition in smokers with HIV.Psychopharmacology · 2020Trial
- Article
- Product Nkabinde Mediates Cytokine Modulation and Antiviral Activity in HIV-Infected MT4 Cells.International journal of molecular sciences · 2026Article
- Brain MR Elastography Metrics Associated with Alterations in Learning and Memory in People with HIV.Research square · 2026Article
- Facilitators and Barriers to Implementing Peer-Led Neurocognitive Screening for Older Adults Living With HIV at a Community Hospital in Thailand: A Multiple-Methods Study.Journal of the International AIDS Society · 2026Article
- Development of a mortality risk prediction model for patients on antiretroviral therapy at Felege Hiwot Comprehensive Specialized Hospital: a retrospective cohort study.Scientific reports · 2026Article
- Antiretroviral Therapy Switching Among People with HIV in the United States is not Uncommon Despite Virologic Suppression: An OPERA Cohort Study.Infectious diseases and therapy · 2026Article
- The kynurenine pathway in relation to depression and anhedonia symptom severity among women with HIV.Brain, behavior, & immunity - health · 2026Article
- Impact of a Trauma-Informed Intervention on Psychosocial and HIV Treatment Outcomes Among Older Adults Living with HIV: A Pilot Study.AIDS and behavior · 2026Article
- Intersecting Burdens: Pain and Psychosocial Stressors in Women with HIV and Type 2 Diabetes - Insights from the MACS/WIHS Combined Cohort Study.Research square · 2026Article
- Cervical Cancer Screening Cascade in Côte d'Ivoire: A Decade of Real-World Program Evaluation According to HIV Status.JCO global oncology · 2026Article
184 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewImproved virological and immunological outcomes and reduced toxicity of antiretroviral combination therapy (ART) raise the hope that life expectancy of HIV-positive persons on ART will approach that of the general population. We systematically review the literature and summarize published estimates of life expectancy of HIV-positive populations on ART. We compare their life expectancy with the life expectancy of the general or, in sub-Saharan Africa, HIV-negative populations, by time period and gender. RECENT
findingsTen relevant studies were published from 2006 to 2015. Three studies were from Canada, two from European countries, three from sub-Saharan Africa and two were multicountry studies. Life expectancy increased over time in all studies and regions. Expressed as the percentage of life expectancy in the HIV-negative or general population, estimated life expectancy at age 20 years in HIV-positive people on ART ranged from 60.3% (95% CI 58.0-62.6%) in Rwanda (2008-2011) to 89.1% (95% CI 84.7-93.6%) in Canada (2008-2012). The percentage of life expectancy in the HIV-negative or general population achieved was higher in HIV-positive women than in HIV-positive men in all countries, except for Canada wherein the opposite was the case. SUMMARY: Life expectancy in HIV-positive people on ART has improved worldwide in recent years, but important gaps remain compared with the general and HIV-negative population, and between regions and genders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.